Trials / Completed
CompletedNCT05537025
Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF). The study will initiate with NHVs receiving single ascending doses of ARO-MMP7. Following evaluation of safety and pharmacodynamic (PD) data, participants will receive multiple doses of ARO-MMP7.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARO-MMP7 Inhalation Solution | ARO-MMP7 by inhalation of nebulized solution |
| DRUG | Placebo | Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution |
Timeline
- Start date
- 2023-01-30
- Primary completion
- 2025-09-05
- Completion
- 2025-09-05
- First posted
- 2022-09-13
- Last updated
- 2025-10-15
Locations
19 sites across 6 countries: Denmark, Italy, New Zealand, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05537025. Inclusion in this directory is not an endorsement.